Fluicell AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FLUI.ST research report →
Companywww.fluicell.com
Fluicell AB (publ) provides single-cell discovery platforms for biomedicine, drug development, and bioprinting applications worldwide. The company offers BioPen PRIME and BioPen FLEX microfluidic systems for maintaining localized solution delivery in single-cell experiments, as well as enabling control of the chemical environment around single intact cells in tissue or cell cultures; and Dynaflow Resolve system, a secondary ion channel screening platform, which allows for recording of various ion channel current in patch-clamp recording configuration. The company was founded in 2012 and is based in Gothenburg, Sweden.
- CEO
- Carolina Trjulja
- IPO
- 2018
- Employees
- 10
- HQ
- Mölndal, SE
Price Chart
Valuation
- Market Cap
- $42.17M
- P/E
- -17.96
- P/S
- 3.55
- P/B
- 2.97
- EV/EBITDA
- -13.82
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 69.30%
- Op Margin
- -28.16%
- Net Margin
- -19.79%
- ROE
- -18.94%
- ROIC
- -23.51%
Growth & Income
- Revenue
- $6.00M · 222.86%
- Net Income
- $-8,332,000 · 46.28%
- EPS
- $-0.10 · 99.24%
- Op Income
- $-8,685,000
- FCF YoY
- 100.00%
Performance & Tape
- 52W High
- $43.10
- 52W Low
- $7.45
- 50D MA
- $16.48
- 200D MA
- $13.11
- Beta
- 1.47
- Avg Volume
- 12.00K
Get TickerSpark's AI analysis on FLUI.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our FLUI.ST Coverage
We haven't published any research on FLUI.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate FLUI.ST Report →